RaySearch Laboratories Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

RaySearch Laboratories şirketinin toplam hissedar öz sermayesi SEK810.7M ve toplam borcu SEK0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla SEK2.0B ve SEK1.2B dir. RaySearch Laboratories 'in FAVÖK'ü SEK238.6M faiz karşılama oranı 117.5 dur. Şirketin SEK425.0M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

Borç/özkaynak oranı

SEK 0

Borç

Faiz karşılama oranı	117.5x
Nakit	SEK 425.03m
Eşitlik	SEK 810.66m
Toplam yükümlülükler	SEK 1.20b
Toplam varlıklar	SEK 2.02b

Son finansal sağlık güncellemeleri

Recent updates

RaySearch Laboratories AB (publ)'s (STO:RAY B) Shares Climb 28% But Its Business Is Yet to Catch Up

Nov 09

RaySearch Laboratories AB (publ) (STO:RAY B) Stocks Shoot Up 28% But Its P/E Still Looks Reasonable

May 21

The Returns At RaySearch Laboratories (STO:RAY B) Aren't Growing

May 11

RaySearch Laboratories (STO:RAY B) Will Want To Turn Around Its Return Trends

Oct 04

Does RaySearch Laboratories (STO:RAY B) Have A Healthy Balance Sheet?

Jul 10

Is RaySearch Laboratories (STO:RAY B) Using Too Much Debt?

Nov 17

One Forecaster Is Now More Bearish On RaySearch Laboratories AB (publ) (STO:RAY B) Than They Used To Be

Mar 15

Is RaySearch Laboratories (STO:RAY B) A Risky Investment?

Feb 22

Is RaySearch Laboratories (STO:RAY B) Using Debt In A Risky Way?

Nov 04

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: RAY B 'nin kısa vadeli varlıkları ( SEK906.6M ) kısa vadeli yükümlülüklerini ( SEK699.7M ) aşıyor.

Uzun Vadeli Yükümlülükler: RAY B şirketinin kısa vadeli varlıkları ( SEK906.6M ) uzun vadeli yükümlülüklerini ( SEK505.1M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: RAY B borçsuzdur.

Borcun Azaltılması: RAY B şirketinin 5 yıl önce borç/öz sermaye oranı 7.2% iken borcu yok.

Borç Kapsamı: RAY B un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: RAY B şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

RaySearch Laboratories Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Does RaySearch Laboratories (STO:RAY B) Have A Healthy Balance Sheet?

Is RaySearch Laboratories (STO:RAY B) Using Too Much Debt?

Is RaySearch Laboratories (STO:RAY B) A Risky Investment?

Is RaySearch Laboratories (STO:RAY B) Using Debt In A Risky Way?

Recent updates

Consensus EPS estimates increase by 16%

Price target increased by 33% to kr260

RaySearch Laboratories AB (publ)'s (STO:RAY B) Shares Climb 28% But Its Business Is Yet to Catch Up

New minor risk - Share price stability

RaySearch Laboratories AB (publ) to Report First Half, 2025 Results on Aug 07, 2025

Investor sentiment improves as stock rises 28%

RaySearch Laboratories AB (publ) to Report First Half, 2025 Results on Aug 08, 2025

RaySearch Laboratories AB (publ) Announces CFO Changes

Consensus EPS estimates increase by 14%

Deputy Chief Executive Officer recently sold kr1.9m worth of stock

RaySearch Laboratories AB (publ) to Report Q1, 2025 Results on May 09, 2025

Second quarter 2024 earnings released: EPS: kr1.79 (vs kr0.32 in 2Q 2023)

Investor sentiment improves as stock rises 23%

RaySearch to Present the Latest Advances in RayStation , RayCare and RayIntelligence At AAPM 2024

RaySearch Releases RayStation 2024B

Price target increased by 44% to kr195

RaySearch Laboratories AB (publ) Releases RayCare 2024A

Now 22% undervalued

Raysearch Laboratories AB (Publ) Apprves Ordinary Dividend for the Year 2023

RaySearch Laboratories AB (publ) (STO:RAY B) Stocks Shoot Up 28% But Its P/E Still Looks Reasonable

First quarter 2024 earnings released: EPS: kr1.07 (vs kr0.51 in 1Q 2023)

Upcoming dividend of kr2.00 per share

The Returns At RaySearch Laboratories (STO:RAY B) Aren't Growing

Raysearch to Present the Latest Advances in Raystation, Raycare and Rayintelligence At Estro 2024

Investor sentiment improves as stock rises 16%

Full year 2023 earnings: EPS misses analyst expectations

RaySearch Laboratories AB (publ) Proposes an Extra Dividend for the Year Ended December 31, 2023, Payable on May 29, 2024

RaySearch Laboratories AB (publ) to Report Fiscal Year 2024 Results on Feb 14, 2025

RaySearch Laboratories AB (publ) Releases Raystation 2024A

Consensus EPS estimates increase by 10%

Third quarter 2023 earnings released: EPS: kr0.63 (vs kr0.29 in 3Q 2022)

RaySearch Laboratories AB (publ) to Report Q2, 2024 Results on Aug 16, 2024

RaySearch Laboratories (STO:RAY B) Will Want To Turn Around Its Return Trends

RaySearch to Showcase Latest Innovations in Raystation, RayCare and RayIntelligence to Be Presented at ASTRO 2023

RaySearch Laboratories AB (Publ) to Showcase the Latest Software Innovations At Astro in San Diego, California, October 1-4

Price target increased by 9.5% to kr115

RaySearch Laboratories AB (publ) to Report Fiscal Year 2023 Results on Feb 23, 2024

Second quarter 2023 earnings released: EPS: kr0.32 (vs kr0.58 loss in 2Q 2022)

RaySearch Laboratories AB (publ) to Report Q1, 2024 Results on May 17, 2024

RaySearch to Present the Latest Advances in Raystation, RayCare and RayIntelligence at AAPM 2023

RaySearch Laboratories AB (Publ) Announces the Release of the Latest Version of RayCare®, the Next Generation Oncology Information System

RaySearch Laboratories AB (publ) Releases Raystation 2023B

Raysearch Laboratories AB (Publ)'s RayCare in clinical use with CyberKnife at Lausanne University Hospital (CHUV) in Switzerland

Does RaySearch Laboratories (STO:RAY B) Have A Healthy Balance Sheet?

Henrik Bergentoft Leaves the Position as CFO for Raysearch

Founder recently sold kr40m worth of stock

New minor risk - Shareholder dilution

RaySearch Laboratories AB (publ) Announce to Exhibit Latest Software Innovations for Particle Therapy and BNCT at PTCOG 2023

First quarter 2023 earnings released

Director recently bought kr88k worth of stock

Founder recently sold kr1.1m worth of stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

RaySearch Laboratories AB (publ) to Report Fiscal Year 2022 Results on Feb 28, 2023

RaySearch Laboratories AB (publ) to Report Q3, 2023 Results on Nov 17, 2023

Third quarter 2022 earnings released

Is RaySearch Laboratories (STO:RAY B) Using Too Much Debt?

High number of new directors

Raysearch Laboratories AB (Publ) Elects Günther Mårder as New Board Member

Now 21% undervalued after recent price drop

Second quarter 2022 earnings released

Now 29% undervalued after recent price drop

Raysearch Laboratories AB (Publ) Appoints Henrik Bergentoft as Cfo, Effective from November 15, 2022

RaySearch Laboratories AB (publ) Launches RayStation 12A

RaySearch to Exhibit the Latest Software Innovations for Particle Therapy at PTCOG 2022

RaySearch Laboratories AB (publ) Releases Latest Version of RayCare

Founder recently sold kr20m worth of stock

First quarter 2022 earnings: Revenues miss analyst expectations

Price target increased to kr105

Raysearch Laboratories AB (Publ) Announces Raystation, Rayintelligence and Raycare to Be Presented At Estro 2022

Price target decreased to kr85.00

Insufficient new directors